体外膜氧合支持热带感染:范围综述
该范围综述汇总了体外膜氧合(ECMO)支持热带感染的现有文献。作者纳入世界卫生组织指定的被忽视热带病或热带地区高发的病毒、细菌、真菌和寄生虫感染,综述ECMO支持这些感染的可行性及临床考虑。结果显示,钩端螺旋体病、类鼻疽和结核适合静脉-静脉ECMO支持,文献中使用频繁,钩端螺旋体病报告生存率高达84%;美洲锥虫病相关心源性休克使用静脉-动脉ECMO作为移植桥接,一个中心报告71%生存率;登革热和疟疾可成功使用静脉-静脉和静脉-动脉ECMO;中东呼吸综合征接受ECMO者病死率相对较高(>65%)。结论认为随着ECMO全球推广,流行区和非流行区可能有更多热带感染患者需要ECMO。
要点
- 钩端螺旋体病适合静脉-静脉ECMO支持,文献中报告生存率高达84%。
- 美洲锥虫病相关心源性休克可使用静脉-动脉ECMO作为移植桥接,一个中心报告71%生存率。
- 中东呼吸综合征患者接受ECMO支持时病死率相对较高(>65%)。
- 登革热和疟疾可成功使用静脉-静脉和静脉-动脉ECMO支持。
- 类鼻疽和结核适合静脉-静脉ECMO支持,文献中使用频繁。
适用人群与场景
- 病毒、细菌、真菌和寄生虫类热带感染患者,包括世界卫生组织指定的被忽视热带病或热带地区高发的感染性疾病。
研究设计与关键结果
- 研究类型为范围综述,系统检索并综述现有文献中ECMO支持热带感染的证据。
- 钩端螺旋体病、类鼻疽和结核适合静脉-静脉ECMO支持,文献中使用频繁,钩端螺旋体病报告生存率高达84%。
- 美洲锥虫病相关心源性休克使用静脉-动脉ECMO作为移植桥接,一个中心报告71%生存率。
- 登革热和疟疾可成功使用静脉-静脉和静脉-动脉ECMO支持。
- 中东呼吸综合征患者接受ECMO支持时病死率相对较高(>65%)。
- 棘球蚴感染可在围手术期使用ECMO支持。
- 多种热带感染的ECMO使用尚未见发表文献。
证据类型、等级与局限
- 证据类型:范围综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,随着ECMO在全球推广,流行区和非流行区可能有更多热带感染患者需要ECMO。
- 作者呈现了ECMO支持热带感染疾病的证据基础,包括特定疾病过程中的可行性和热带疾病在ECMO回路上的临床考虑。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) for infectious causes of refractory cardiopulmonary failure is established as appropriate therapy in high-income countries. Its use in low- and middle-income nations for tropical infections is not well-studied, however, perhaps because most of these countries have not been historically able to offer ECMO support. Tropical infections remain an important cause of global morbidity and mortality, but the role of ECMO is poorly described.
METHODS: We identified a list of viral, bacterial, fungal, and parasitic infections that qualified as tropical infectious diseases. These included infections that were either a World Health Organization (WHO) designated Neglected Tropical Disease (NTD) or an infectious disease with a higher prevalence in the Tropics than elsewhere. We conducted a comprehensive review of existing literature regarding ECMO use to support these infections.
RESULTS: Multiple viral, bacterial, fungal, and parasitic tropical infections have been supported by ECMO with varying success. leptospirosis, melioidosis, and tuberculosis are conditions suitable for venovenous ECMO support with frequent use in the literature and reported survival as high as 84% in Leptospirosis. Venoarterial ECMO has been successfully used in American trypanosomiasis-related cardiogenic shock as a bridge to transplant, with one center reporting a 71% survival rate. Dengue and malaria have been successfully supported with both venovenous and venoarterial ECMO. Mortality is relatively high (> 65%) in patients who receive ECMO for Middle Eastern Respiratory Syndrome. ECMO has also supported Echinococcal infections perioperatively. There are multiple tropical infections where ECMO use has not been published.
CONCLUSION: As the use of ECMO expands globally, more patients with tropical infections may require ECMO in both endemic and non-endemic settings. We present a scoping review on the evidence base of ECMO use to support tropical infectious diseases, with data regarding feasibility in specific disease processes as well as clinical considerations for tropical diseases on the ECMO circuit.
参考来源
- Jarrett ZS, Marcus JE, Salazar L, et al. Extracorporeal membrane oxygenation support for tropical infections: a scoping review. J Intensive Care. 2026. PMID: 41485007. doi:10.1186/s40560-025-00843-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。